Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessing expression patterns of PTGR1, a potential biomarker for acylfulven sensitivity in urothelial carcinoma.

Scientific reports - 10 Nov 2024

Stormoen Dag Rune, Lehn Signe, Mouw Kent W, Szallasi Zoltan, Melchior Linea Cecilie, Dohn Line Hammer, Börcsok Judit, Rossing Maria, Toft Birgitte Grønkaer, Pappot Helle

Abstract excerpt

BACKGROUND: Metastatic urothelial carcinoma (mUC) has a poor prognosis, despite recent therapeutic advancements. Prostaglandin Reductase 1 (PTGR1) is essential for activating acylfulvens, a promising class of drugs for treating a subset of urothelial carcinoma (UC) patients. The efficacy of acylfulvens depends on PTGR1 activity and defects in the nucleotide excision repair (NER) pathway, notably ERCC2 mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Transitional Cell

Share to Cell Line, Tumor

Share to Gene Expression Regulation, Neoplastic

Share to Immunohistochemistry

Share to Prognosis

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 39523403
DOI: 10.1038/s41598-024-79334-x
PMCID: PMC11551215

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Assessing expression patterns of PTGR1, a potential biomarker for acylfulven sensitivity in urothelial carcinoma.PMID 39523403Read ↗

Doctors revise Declaration of HelsinkiSemantic proximity Read ↗

The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival ProbabilitySemantic proximity Read ↗

Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer.Semantic proximity Read ↗

Recommendations for the optimal management of early and advanced urothelial carcinoma.Semantic proximity Read ↗

The Genomic Landscape of Urothelial Carcinoma with High and Low ERBB2 ExpressionSemantic proximity Read ↗

HER2 as a target in invasive urothelial carcinoma.Semantic proximity Read ↗

TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinomaSemantic proximity Read ↗

Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial CancerSemantic proximity Read ↗

The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.Semantic proximity Read ↗

Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial CarcinomaSemantic proximity Read ↗

Real-world performance of Uromonitor® in urothelial bladder cancer detection: a multicentric trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.